1
MULTIPLE SCLEROSIS SØGNING UDFØRT 27. MAJ 2013
v/ søgekonsulent Kirsten Birkefoss, [email protected]
Kontaktperson: Birgitte Holm Petersen, [email protected]
Klik på titlen, der linker til de enkelte guidelines (undtagen HTA Database) Der er søgt i:
GIN (International)
NICE (UK) National Guideline Clearinghouse (USA) SIGN (Skotland)
HTA Database (UK) Cochrane
SBU (Sverige) Socialstyrelsen (Sverige) Kunnskapssenteret (Norge)
Helsedirektoratet (Norge) Helsebiblioteket (Norge)
Pedro OTSeeker National Health and Medical Research Council (Australia)
PubMed Cinahl
Der er kun brugt tidsafgrænsningen, 2003-2013 I databaserne Pubmed og Cinahl.
GIN (password restricted) Søgt på: multiple sclerosis (engelsk, dansk, svensk norsk)
4 fund, som også er fundet i NICE og SBU (se fund i disse databaser
nedenfor)
NICE (UK)
Søgt på: multiple sclerosis (guideline)
11 fund 1)
Multiple sclerosis (CG8)
The summary of the published clinical guideline on Multiple sclerosis. It links to the published
guidance and key documents.
mailto:[email protected]:[email protected]://www.nice.org.uk/_gs/searchtracker/GUIDANCE/10930
2
View the summary and implementation tools 01 November 2003
o Full Guidance o NICE Guidance
o Information for the public
Multiple sclerosis
Multiple sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (brain and
spinal cord). The disease process is one of episodes where white matter within the brain or spinal cord
becomes inflamed and then destroyed by the person's own
Appendix F: Diagnosis of multiple sclerosis
Appendix F: Diagnosis of multiple sclerosis The full guideline contains this information.
Rapid diagnosis
Rapid diagnosis An individual who is suspected of having multiple sclerosis should be referred to a
specialist neurology service, and seen rapidly within an audited time. The individual should be seen
again after all investigations necessary to confirm
2)
Multiple sclerosis (2014)
Management of multiple sclerosis in primary and secondary care
Status: Referred
Publication date: TBC
Wave: R
Process: CG
Topic area:
Central nervous system
Project team | Schedule | Project history | Key documents
NICE project team
Centre for clinical practice lead: Christine Carson
Communications manager: Paul Cooney
Guidelines commissioning manager: Caroline Keir
Guidelines coordinator: Margaret Ghlaimi
Patient involvement lead: Barbara Meredith
http://guidance.nice.org.uk/CG8http://guidance.nice.org.uk/CG8/Guidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/NICEGuidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://publications.nice.org.uk/multiple-sclerosis-cg8/multiple-sclerosishttp://publications.nice.org.uk/multiple-sclerosis-cg8/appendix-f-diagnosis-of-multiple-sclerosishttp://publications.nice.org.uk/multiple-sclerosis-cg8/key-priorities-for-implementation#rapid-diagnosishttp://guidance.nice.org.uk/CG/WaveR/115#projectTeamhttp://guidance.nice.org.uk/CG/WaveR/115#schedulehttp://guidance.nice.org.uk/CG/WaveR/115#historyhttp://guidance.nice.org.uk/CG/WaveR/115#keydocs
3
Implementation lead: TBC
Guidelines Development Group: The Guideline Development Group (GDG) oversees the development process.
Email enquiriesIf you have any queries please email [email protected]
Provisional schedule
Scoping workshop: 05 April 2012
Consultation on draft scope with stakeholders: 8 May - 7 June 2012
Consultation on draft guideline with stakeholders: TBC
Publication date: TBC
Project history
Date Update
3 August 2012
The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table. The Guideline Development Group (GDG) oversees the development process.
8 May 2012
The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.
31 October 2011
The first draft of the scope is currently in preparation. The scope will define what aspects of care the guideline will cover and to whom it will apply.
Top
Top
mailto:[email protected]://guidance.nice.org.uk/_gs/link/?id=1717E5BD-19B9-E0B5-D4E01089A7EDB94Bhttp://guidance.nice.org.uk/CG/WaveR/115#pagetophttp://guidance.nice.org.uk/CG/WaveR/115#pagetop
4
Key documents
Multiple sclerosis (2014): scoping workshop, consultation and final scope 29 August 2012
Multiple Sclerosis (2014): guideline development and consultation 03 August 2012
Multiple sclerosis (2014): list of stakeholders and how to register 16 May 2012
Multiple sclerosis (2014): stakeholder list 08 May 2012
Multiple Sclerosis (update): NCC information 31 October 2011
Multiple Sclerosis (update): The Guideline Development Process - an overview for stakeholders, the public and the NHS
31 October 2011
This page was last updated: 24 May 2013
3) Multiple sclerosis - natalizumab (TA127) The summary of the published technology appraisal on Multiple sclerosis - natalizumab. It links to the published guidance and key documents. View the summary and implementation tools22 August 2007 Full Guidance Quick reference guide
Information for the public
4) Guidance issued Multiple sclerosis (CG8) The summary of the published clinical guideline on Multiple sclerosis. It links to the published guidance and key documents. View the summary and implementation tools01 November 2003 Full Guidance NICE Guidance
Information for the public
5) Guidance issuedMultiple sclerosis (relapsing-remitting) - fingolimod (TA254) The summary of the published technology appraisal on Multiple sclerosis (relapsing-remitting) - fingolimod. It links to the published guidance and key documents. View the summary and implementation tools25 April 2012 Full Guidance
Information for the public
Top
http://guidance.nice.org.uk/CG/WaveR/115/Scopinghttp://guidance.nice.org.uk/CG/WaveR/115/Developmenthttp://guidance.nice.org.uk/guidance/index.jsp?action=folder&o=59243http://guidance.nice.org.uk/CG/WaveR/115/SHList/pdf/Englishhttp://guidance.nice.org.uk/_gs/link/?id=59E25114-19B9-E0B5-D4894577AB2795FDhttp://guidance.nice.org.uk/_gs/link/?id=59E00F28-19B9-E0B5-D4B352883C38FAD8http://guidance.nice.org.uk/_gs/link/?id=59E00F28-19B9-E0B5-D4B352883C38FAD8http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11822http://guidance.nice.org.uk/TA127http://guidance.nice.org.uk/TA127/Guidance/pdf/Englishhttp://guidance.nice.org.uk/TA127/QuickRefGuide/pdf/Englishhttp://guidance.nice.org.uk/TA127/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/TA127/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/10930http://guidance.nice.org.uk/CG8http://guidance.nice.org.uk/CG8/Guidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/NICEGuidance/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG8/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13719http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13719http://guidance.nice.org.uk/TA254http://guidance.nice.org.uk/TA254/Guidance/pdf/Englishhttp://guidance.nice.org.uk/TA254/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/TA254/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/CG/WaveR/115#pagetop
5
6) Guidance issuedPercutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis (IPG420) The summary of the published interventional procedure on Percutaneous venoplasty for chronic cerebrospinal venous insufficiency for multiple sclerosis. It links to the published guidance and key documents. View the summary and implementation tools28 March 2012 Full Guidance
Information for the public
7) Guidance issuedMultiple sclerosis - beta interferon and glatiramer acetate (TA32) The summary of the published technology appraisal on Multiple sclerosis - beta interferon and glatiramer acetate. It links to the published guidance and key documents. View the summary and implementation tools01 January 2002 Full Guidance
8) SuspendedMultiple sclerosis - cladribine [ID64] The summary of the suspended technology appraisal on Multiple sclerosis - cladribine [ID64]. It links to the suspended guidance and key documents.
9) DiscontinuedMultiple sclerosis - sativex [ID387] The summary of the discontinued technology appraisal on Multiple sclerosis - sativex [ID387]. It links to the discontinued guidance and key documents.
10) In progressMultiple sclerosis (primary-progressive) - fingolimod [ID62] The summary of the in development technology appraisal on Multiple sclerosis (primary-progressive) - fingolimod [ID62]. It links to the key documents, details of NICE staff and external stakeholders involved in developing NICE guidance.
11) In progressMultiple sclerosis (relapsing-remitting) - laquinimod [ID560] The summary of the in development technology appraisal on Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]. It links to the key documents, details of NICE staff and external stakeholders involved in developing NICE guidance.
http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/13064http://guidance.nice.org.uk/IPG420http://guidance.nice.org.uk/IPG420/Guidance/pdf/Englishhttp://guidance.nice.org.uk/IPG420/PublicInfo/pdf/Englishhttp://guidance.nice.org.uk/IPG420/PublicInfo/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11441http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11441http://guidance.nice.org.uk/TA32http://guidance.nice.org.uk/TA32/Guidance/pdf/Englishhttp://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11896http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/11681http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/12171http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/12171http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/14058http://www.nice.org.uk/_gs/searchtracker/GUIDANCE/14058
6
National Guideline Clearinghouse (USA)
1-20 of 58 Next >
1. Comparison of Multiple Sclerosis Guidelines Underscores Need for Collaboration
Compare Selected
2. Fingolimod for the treatment of highly active relapsing-
remitting multiple sclerosis. 2012 Apr. NGC:009075 National Institute for Health and Care Excellence (NICE) -
National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
Compare
Selected
3. Evidence report: the efficacy and safety of mitoxantrone
(Novantrone) in the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology. 2003 Nov 25 (revised 2010 May). NGC:008150
American Academy of Neurology - Medical Specialty Society. View all guidelines by the developer(s)
Compare
Selected
4. Nursing management of the patient with multiple sclerosis. 2011. NGC:009286
American Association of Neuroscience Nurses - Professional Association; Association of Rehabilitation Nurses - Professional
Association; International Organization of Multiple Sclerosis Nurses - Professional Association. View all guidelines by the
developer(s)
Compare Selected
5. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based
review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of
Neurology. 2008 Sep 2. NGC:006705 American Academy of Neurology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare Selected
6. Use of imaging in multiple sclerosis. 2006 Apr (revised
2011). NGC:008784 European Federation of Neurological Societies - Medical
Specialty Society. View all guidelines by the developer(s)
Compare
Selected
7. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology
Society. 2003 Sep 9 (reaffirmed 2008 Nov 15). NGC:003154
Compare Selected
javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbNext','')http://guideline.gov/expert/expert-commentary.aspx?id=16443&search=multiple+sclerosishttp://guideline.gov/expert/expert-commentary.aspx?id=16443&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36885&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36885&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1178http://guideline.gov/browse/by-organization.aspx?orgid=1178http://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24497&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=38259&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38259&search=multiple+sclerosisjavascript:LaunchDevs('38259');javascript:LaunchDevs('38259');http://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13011&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=34911&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4109&search=multiple+sclerosis
7
American Academy of Neurology - Medical Specialty Society; Child Neurology Society - Medical Specialty Society. View all
guidelines by the developer(s)
8. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. 2002
Jan 22 (reaffirmed 2008 Jul 19). NGC:003144
American Academy of Neurology - Medical Specialty Society; Multiple Sclerosis Council - Disease Specific Society. View all
guidelines by the developer(s)
Compare Selected
9. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and
Technology Assessment Subcommittee of the American Academy of Neurology. 1996 (revised 2011 Jan 18).
NGC:008274 American Academy of Neurology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare Selected
10. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases.
2008 Sep. NGC:006937 European Federation of Neurological Societies - Medical
Specialty Society. View all guidelines by the developer(s)
Compare Selected
11. Dementia in the long-term care setting. 1998 (revised
2009). [NGC Update Pending] NGC:007639 American Medical Directors Association - Professional
Association. View all guidelines by the developer(s)
Compare
Selected
12. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. 2006 Nov (revised 2010
Sep). NGC:008162 European Federation of Neurological Societies - Medical
Specialty Society. View all guidelines by the developer(s)
Compare Selected
13. Urinary incontinence in neurological disease. Management of lower urinary tract dysfunction in
neurological disease. 2012 Aug. NGC:009310 National Clinical Guideline Centre - National Government
Agency [Non-U.S.]. View all guidelines by the developer(s)
Compare Selected
14. Guidelines of care for the management of psoriasis and
psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with
biologics. 2008 May. NGC:006435 American Academy of Dermatology - Medical Specialty
Society. View all guidelines by the developer(s)
Compare
Selected
15. ACR Appropriateness Criteria® cranial neuropathy. Compare
javascript:LaunchDevs('4109');javascript:LaunchDevs('4109');http://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=4099&search=multiple+sclerosisjavascript:LaunchDevs('4099');javascript:LaunchDevs('4099');http://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=25656&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=13565&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13565&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=15594&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=771http://guideline.gov/content.aspx?id=24525&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24525&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38411&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2317http://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12505&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=36http://guideline.gov/content.aspx?id=37947&search=multiple+sclerosis
8
2009 (revised 2012). NGC:009252 American College of Radiology - Medical Specialty Society.
View all guidelines by the developer(s)
Selected
16. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Report of the
Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
2011 Dec 13. NGC:008839
American Academy of Neurology - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
17. Ulcerative colitis practice guidelines in adults:
American College of Gastroenterology, Practice Parameters Committee. 2010 Mar. NGC:009292
American College of Gastroenterology - Medical Specialty Society. View all guidelines by the developer(s)
Compare
Selected
18. Nystagmus and oscillopsia. 2004 Feb (revised 2012 Jan).
NGC:009361 European Federation of Neurological Societies - Medical
Specialty Society. View all guidelines by the developer(s)
Compare
Selected
19. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the
treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
2011 Jul. NGC:009039
American Academy of Dermatology - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
20. BSR and BHPR rheumatoid arthritis guidelines on
safety of anti-TNF therapies. 2001 (revised 2010). NGC:009434
British Health Professionals in Rheumatology - Professional Association; British Society for Rheumatology - Medical
Specialty Society. View all guidelines by the developer(s)
Compare
Selected
1-20 of 58 Next >
21-40 of 58 < Previous | Next >
21. Guidelines on neurogenic lower urinary tract
dysfunction. 2003 (revised 2011 Mar). NGC:008601 European Association of Urology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare
Selected
22. Palliative care. 2007 Jan (revised 2011 Nov). NGC:008961 Institute for Clinical Systems Improvement - Nonprofit
Organization. View all guidelines by the developer(s)
Compare Selected
http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=35116&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38323&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=588http://guideline.gov/content.aspx?id=38472&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36824&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=36http://guideline.gov/content.aspx?id=38656&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38656&search=multiple+sclerosisjavascript:LaunchDevs('38656');javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbNext','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbPrev','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbNext','')http://guideline.gov/content.aspx?id=34062&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34062&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2034http://guideline.gov/content.aspx?id=36058&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722
9
23. Screening and Risk Assessment for Osteoporosis
Compare Selected
24. ACR Appropriateness Criteria® ataxia. 1999 (revised
2012). NGC:009237 American College of Radiology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare
Selected
25. ACR Appropriateness Criteria® focal neurologic deficit. 2006 (revised 2012). NGC:009223
American College of Radiology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare Selected
26. Chronic fatigue syndrome/myalgic encephalomyelitis. A primer for clinical practitioners. 2012. NGC:009288
International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis - Nonprofit
Organization. View all guidelines by the developer(s)
Compare Selected
27. Hip and groin disorders. 2011. NGC:009298 American College of Occupational and Environmental
Medicine - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
28. ACR Appropriateness Criteria® orbits, vision and visual
loss. 1999 (revised 2012). NGC:009239 American College of Radiology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare
Selected
29. Routine cerebrospinal fluid (CSF) analysis. 2006 Sep
(revised 2011). NGC:008781 European Federation of Neurological Societies - Medical
Specialty Society. View all guidelines by the developer(s)
Compare
Selected
30. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from
the American College of Physicians. 2009 Nov 3. NGC:007688
American College of Physicians - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
31. Evidence-based guideline: intravenous immunoglobulin
in the treatment of neuromuscular disorders. Report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology. 2012 Mar 27. NGC:009085
American Academy of Neurology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare
Selected
32. ACR Appropriateness Criteria® cerebrovascular disease. 1996 (revised 2011). NGC:008482
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
http://guideline.gov/syntheses/synthesis.aspx?id=38658&search=multiple+sclerosishttp://guideline.gov/syntheses/synthesis.aspx?id=38658&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37932&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=37918&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38316&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38316&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2350http://guideline.gov/content.aspx?id=38357&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=446http://guideline.gov/browse/by-organization.aspx?orgid=446http://guideline.gov/content.aspx?id=37934&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37934&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=34908&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15652&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=140http://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36895&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=32645&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32645&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246
10
33. Occupational therapy practice guidelines for adults with traumatic brain injury. 2009. NGC:007509
American Occupational Therapy Association, Inc. - Professional Association. View all guidelines by the
developer(s)
Compare Selected
34. Risk factor assessment for osteoporosis and/or increased fracture risk in men. 2008 May. NGC:006587
University of Texas at Austin School of Nursing, Family Nurse
Practitioner Program - Academic Institution. View all guidelines by the developer(s)
Compare Selected
35. Assessment: botulinum neurotoxin in the treatment of
autonomic disorders and pain (an evidence-based review). Report of the Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology. 2008 May 6. NGC:006658
American Academy of Neurology - Medical Specialty Society. View all guidelines by the developer(s)
Compare
Selected
36. Pressure ulcer prevention and treatment protocol.
Health care protocol. 2008 Jan (revised 2012 Jan). NGC:008962
Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)
Compare
Selected
37. Association for the Advancement of Wound Care
guideline of pressure ulcer guidelines. 2010 Oct 1.
NGC:008120 Association for the Advancement of Wound Care - Nonprofit
Organization. View all guidelines by the developer(s)
Compare
Selected
38. Major depression in adults in primary care. 1996 Jan (revised 2012 May). NGC:009117
Institute for Clinical Systems Improvement - Nonprofit Organization. View all guidelines by the developer(s)
Compare Selected
39. VA/DoD clinical practice guideline for management of
major depressive disorder (MDD). 1997 (revised 2009 May). NGC:007711
Department of Defense - Federal Government Agency [U.S.]; Department of Veterans Affairs - Federal Government Agency
[U.S.]; Veterans Health Administration - Federal Government Agency [U.S.]. View all guidelines by the developer(s)
Compare
Selected
40. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based
review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
and the European Federation of Neurological Societies. 2008 Oct 7. NGC:006700
American Academy of Neurology - Medical Specialty Society;
Compare Selected
http://guideline.gov/content.aspx?id=15287&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15287&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=165http://guideline.gov/browse/by-organization.aspx?orgid=165http://guideline.gov/content.aspx?id=12785&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12785&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1096http://guideline.gov/browse/by-organization.aspx?orgid=1096http://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=12948&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=36059&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36059&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=24361&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24361&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1736http://guideline.gov/content.aspx?id=37277&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=15675&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15675&search=multiple+sclerosisjavascript:LaunchDevs('15675');http://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=13006&search=multiple+sclerosis
11
European Federation of Neurological Societies - Medical Specialty Society. View all guidelines by the developer(s)
21-40 of 58 < Previous | Next >
41-58 of 58 < Previous
41. Urinary incontinence in women. 2001 Jan 4 (revised 2008 Aug 8). NGC:006743
Finnish Medical Society Duodecim - Professional Association. View all guidelines by the developer(s)
Compare Selected
42. ACR Appropriateness Criteria® vertigo and hearing loss. 1996 (revised 2008). NGC:007784
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
43. Screening for hearing loss in older adults: U.S.
Preventive Services Task Force recommendation statement. 1996 (revised 2012 Nov 6). NGC:009297
U.S. Preventive Services Task Force - Independent Expert Panel. View all guidelines by the developer(s)
Compare
Selected
44. Assessment and management of chronic pain. 2005 Nov
(revised 2011 Nov). NGC:008967 Institute for Clinical Systems Improvement - Nonprofit
Organization. View all guidelines by the developer(s)
Compare
Selected
45. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. 1996
Feb (revised 2010 Oct). NGC:008113
American Academy of Sleep Medicine - Professional Association. View all guidelines by the developer(s)
Compare Selected
46. Best evidence statement (BESt). Wheelchair delivery
evaluation. 2010 Nov. NGC:008529 Cincinnati Children's Hospital Medical Center - Hospital/Medical
Center. View all guidelines by the developer(s)
Compare
Selected
47. Sleep disorders in neurodegenerative disorders and stroke. 2007 Nov (revised 2011). NGC:008782
European Federation of Neurological Societies - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
48. ACR Appropriateness Criteria® dementia and movement
disorders. 1996 (revised 2010). NGC:008455 American College of Radiology - Medical Specialty Society. View
all guidelines by the developer(s)
Compare
Selected
49. Lymphoma. 2012 Sep. NGC:009392
Alberta Health Services, Cancer Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
Compare
Selected
javascript:LaunchDevs('13006');javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbPrev','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl24$lbNext','')javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl01$lbPrev','')http://guideline.gov/content.aspx?id=13195&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1110http://guideline.gov/content.aspx?id=15749&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=38356&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=345http://guideline.gov/content.aspx?id=36064&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=24178&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=24178&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=105http://guideline.gov/content.aspx?id=33282&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=33282&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=925http://guideline.gov/content.aspx?id=34909&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34909&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=1856http://guideline.gov/content.aspx?id=32612&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32612&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=38593&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=2278
12
50. American College of Rheumatology guidelines for screening, treatment, and management of lupus
nephritis. 2012 Jun. NGC:009090 American College of Rheumatology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare Selected
51. Immunizations. 2007 Oct (revised 2012 Mar). NGC:009028 Institute for Clinical Systems Improvement - Nonprofit
Organization. View all guidelines by the developer(s)
Compare Selected
52. Oral hygiene care for functionally dependent and
cognitively impaired older adults. 2002 Nov (revised 2011
Jul). NGC:008700 University of Iowa College of Nursing, John A. Hartford
Foundation Center of Geriatric Nursing Excellence - Academic Institution. View all guidelines by the developer(s)
Compare
Selected
53. ACR Appropriateness Criteria® Hodgkin's lymphoma—
favorable prognosis stage I and II. 1999 (revised 2011). NGC:008470
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
Compare
Selected
54. ACR Appropriateness Criteria® seizures and epilepsy.
1996 (revised 2011). NGC:008451 American College of Radiology - Medical Specialty Society. View
all guidelines by the developer(s)
Compare
Selected
55. ACR Appropriateness Criteria® dysphagia. 1998 (revised
2010). NGC:007921 American College of Radiology - Medical Specialty Society. View
all guidelines by the developer(s)
Compare
Selected
56. ACR Appropriateness Criteria® limping child — ages 0-5 years. 1995 (revised 2012). NGC:009219
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
Compare Selected
57. Practice parameter update: the care of the patient with
amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Report
of the Quality Standards Subcommittee of the American Academy of Neurology. 1999 Apr (revised 2009 Oct 13).
NGC:007839 American Academy of Neurology - Medical Specialty Society.
View all guidelines by the developer(s)
Compare
Selected
58. Practice parameter update: the care of the patient with
amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral
impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American
Compare
Selected
http://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=36900&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=586http://guideline.gov/content.aspx?id=36813&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=722http://guideline.gov/content.aspx?id=34447&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=34447&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=930http://guideline.gov/content.aspx?id=32633&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=32633&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=32608&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=23815&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=37914&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=37914&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/browse/by-organization.aspx?orgid=246http://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15953&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39http://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/content.aspx?id=15954&search=multiple+sclerosis
13
Academy of Neurology. 1999 Apr (revised 2009 Oct 13). NGC:007840
American Academy of Neurology - Medical Specialty Society. View all guidelines by the developer(s)
41-58 of 58 < Previous
SIGN (Skotland)
0 fund
HTA Database (The University of York, Centre for Reviews and
Dissemination) Søgt på: multiple sclerosis
66 fund
Results for: (multiple sclerosis):TI IN HTA
1 2012
HTA NIHR Horizon Scanning
Centre (NIHR HSC) BIIB-017
for relapsing
forms of
multiple
sclerosis [Preview]
2 2012 HTA Catalan Agency for
Health
Information,
Assessment
[Clinical practice
guideline of care for
people with multiple
sclerosis] [Preview]
http://guideline.gov/content.aspx?id=15954&search=multiple+sclerosishttp://guideline.gov/browse/by-organization.aspx?orgid=39javascript:__doPostBack('ctl00$ContentPlaceHolder1$ctrlResults$gvResults$ctl22$lbPrev','')
14
and Quality
(CAHIAQ -
formerly
CAHTA)
3 2012 HTA L'Institut national
d'excellence
en sante et en
services
sociaux
(INESSS)
Diagnosis and
treatment of chronic
cerebrospinal
venous insufficiency
(CCSVI) for people
with multiple
sclerosis [Preview]
4 2012 HTA L'Institut national
d'excellence
en sante et en
services
sociaux
(INESSS)
[Diagnosis and
treatment of Chronic
Cerebrospinal
Venous
Insufficiency
(CCSVI) in people
with Multiple
Sclerosis (MS)] [Preview]
5 2012 HTA Canadian Agency for
Drugs and
Technologies
in Health
(CADTH)
Modafinil for sleep
disorders and
fatigue secondary to
multiple sclerosis: a
review of the
clinical efficacy and
safety [Preview]
6 2011 HTA Institute for Clinical
Effectiveness
and Health
Policy (IECS)
[Dalfampridine
(ampyra) in multiple
sclerosis patients] [Preview]
7 2011 HTA National Horizon
Scanning
Centre
(NHSC)
Dimethyl fumarate
for relapsing-
remitting multiple
sclerosis [Preview]
8 2011 HTA HAYES, Inc. Functional Electrical Stimulation (FES)
for treatment of foot
drop in multiple
15
sclerosis patients [Preview]
9 2011 HTA National Horizon
Scanning
Centre
(NHSC)
Laquinimod for
multiple sclerosis:
relapsing-remitting -
first or second line. [Preview]
10 2011 HTA HAYES, Inc. Neutralizing Antibody (NAb)
testing using the
myxovirus protein A
(MxA) assay to
assess interferon
beta treatment of
multiple sclerosis [Preview]
11 2011 HTA National Horizon
Scanning
Centre
(NHSC)
Teriflunomide for
relapsing multiple
sclerosis (MS) - first
line [Preview]
12 2010 HTA National Horizon
Scanning
Centre
(NHSC)
Fampridine-PR for
multiple sclerosis:
impaired mobility -
first line [Preview]
13 2010 HTA HAYES, Inc. High-dose immunosuppressive
therapy with or
without
hematopoietic
transplantation for
the treatment of
multiple sclerosis [Preview]
14 2010 HTA HAYES, Inc. Neutralizing antibody (NAb)
testing using the
cytopathic effect
(CPE) assay to
16
assess interferon
beta treatment of
multiple sclerosis [Preview]
15 2010 HTA HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and
Biogen Idec Inc.)
for multiple
sclerosis [Preview]
16 2009 HTA NIHR Health Technology
Assessment
programme
Improving the
evaluation of
therapeutic
interventions in
multiple sclerosis:
the role of new
psychometric
methods [Preview]
17 2009 HTA HAYES, Inc. Natalizumab (Tysabri, Biogen
Idec and Elan
Pharmaceuticals) for
relapsing remitting
multiple sclerosis [Preview]
18 2009 HTA National Horizon
Scanning
Centre
(NHSC)
Sativex for
spasticity in
multiple sclerosis [Preview]
19 2008 HTA National Horizon
Scanning
Centre
(NHSC)
Cladribine
(Movectro) for
multiple sclerosis;
relapsing-remitting [Preview]
20 2008 HTA National Horizon
Scanning
Centre
(NHSC)
Dirucotide for
secondary
progressive multiple
sclerosis [Preview]
17
21 2008 HTA German Agency for
Health
Technology
Assessment at
the German
Institute for
Medical
Documentation
and
Information
(DAHTA@
DIMDI)
[Interferons
and
natalizumab
for multiple
sclerosis] [Preview]
22
2008 HTA Institute for Clinical
Effectiveness
and Health
Policy (IECS)
T-cell vaccines for
the treatment of
multiple sclerosis [Preview]
23
2007 HTA HAYES, Inc. 3.0 Tesla (3T) Magnetic
Resonance Imaging
(MRI) for multiple
sclerosis [Preview]
24
2007 HTA National Institute for
Health and
Clinical
Excellence
(NICE)
Natalizumab for the
treatment of adults
with highly active
relapsing-remitting
multiple sclerosis [Preview]
25
2006 HTA VA Technology
Assessment
Program
(VATAP)
Bone marrow
transplantation for
treatment of
multiple sclerosis [Preview]
26
2006 HTA HAYES, Inc. Deep brain stimulation for
treatment of
movement
disorders of
multiple sclerosis [Preview]
18
27
2006 HTA HAYES, Inc. Plasma exchange for multiple
sclerosis [Preview]
28
2006 HTA Technology Assessment
Unit of the
McGill
University
Health Centre
(MUHC)
The use of
mitoxantrone in the
treatment of
patients with
multiple sclerosis:
report update [Preview]
29
2006 HTA HAYES, Inc. Visual evoked potentials in the
diagnosis/prognosis
of multiple
sclerosis [Preview]
30
2005 HTA HAYES, Inc. Intrathecal baclofen for spasticity of
spinal origin or due
to multiple
sclerosis [Preview]
31
2005 HTA HAYES, Inc. Intravenous immunoglobulin
for multiple
sclerosis [Preview]
32
2005 HTA Canadian Coordinating
Office for
Health
Technology
Assessment
(CCOHTA)
Sativex for the
management of
multiple sclerosis
symptoms [Preview]
33
2004 HTA University HealthSystem
Consortium
(UHC)
Agents for multiple
sclerosis (TCR) [Preview]
34
2004 HTA Agency for Healthcare
Criteria to
determine disability
19
Research and
Quality
(AHRQ)
related to multiple
sclerosis [Preview]
35
2004 HTA NIHR Health Technology
Assessment
programme
Improving the
evaluation of
therapeutic
interventions in
multiple sclerosis:
development of a
patient-based
measure of
outcome [Preview]
36
2004 HTA HAYES, Inc. Interferon beta for multiple sclerosis [Preview]
37
2004 HTA NIHR Health Technology
Assessment
programme
Methods for
expected value of
information
analysis in complex
health economic
models:
developments on
the health
economics of
interferon-beta and
glatiramer acetate
for multiple
sclerosis [Preview]
38
2003 HTA National Institute for
Clinical
Excellence
(NICE)
Multiple sclerosis:
management of
multiple sclerosis
in primary and
secondary care [Preview]
39
2003 HTA NIHR Health Technology
Assessment
programme
Treatments for
spasticity and pain
in multiple
sclerosis: a
systematic review [Preview]
20
40
2002 HTA NIHR Health Technology
Assessment
programme
A review of the
natural history and
epidemiology of
multiple sclerosis:
implications for
resource allocation
and health
economic models [Preview]
41
2002 HTA National Institute for Clinical
Excellence
(NICE)
Guidance on the use of beta
interferon and glatiramer acetate
for the treatment of multiple
sclerosis [Preview]
42
2002 HTA Bazian Ltd, Wessex Institute
for Health
Research and
Development
(WIHRD)
Hyperbaric oxygen therapy for
multiple sclerosis [Preview]
43
2002 HTA ECRI Interferon beta [IFNb] -1a and -1b for treatment of relapsing-
remitting multiple sclerosis [Preview]
44
2002 HTA National Horizon Scanning Centre
(NHSC)
Mitoxantrone for multiple
sclerosis - horizon scanning
review [Preview]
45
2002 HTA National Horizon Scanning Centre
(NHSC)
Natalizumab for multiple
sclerosis - horizon scanning
review [Preview]
46
2002 HTA Technology Assessment Unit
of the McGill
University Health
Centre (MUHC)
Should the McGill University
Health Center use mitoxantrone
in the treatment of multiple
sclerosis? [Preview]
47
2001 HTA Institute for Clinical Systems
Interferon beta-1a, interferon
beta-1b, glatiramer acetate, and
21
Improvement
(ICSI) mitoxantrone (for treatment of
multiple sclerosis) [Preview]
48
HTA ECRI Plasmapheresis for the treatment of multiple sclerosis [Preview]
49
2001 HTA NIHR Health Technology
Assessment
programme
The role of the specialist nurse in
multiple sclerosis: a rapid and
systematic review [Preview]
50
2000 HTA NIHR Health Technology
Assessment
programme
Disease-modifying drugs for
multiple sclerosis: a rapid and
systematic review [Preview]
51
2000 HTA NIHR Health Technology
Assessment
programme
Treatments for fatigue in
multiple sclerosis: a rapid and
systematic review [Preview]
52 1999 HTA Wessex Institute
for Health
Research and
Development
(WIHRD)
Beta intererons (1a and 1b) in
elapsing-remitting and secondary
progressive multiple sclerosis [Preview]
53 1999 HTA Danish Centre for
Evaluation and
Health
Technology
Assessment
(DACEHTA)
[Beta-interferon treatment in
RRMS and secondary
progressive multiple sclerosis] [Preview]
54 1999 HTA NIHR Health
Technology
Assessment
programme
Development of the protocol for
the proposed trial of beta
interferon in multiple sclerosis [Preview]
55 1999 HTA Danish Centre for
Evaluation and
Health
Technology
Assessment
(DACEHTA)
Interferon beta treatment for
multiple sclerosis (funded by
DIHTA) [Preview]
56 1998 HTA NIHR Health A cost-utility analysis of
22
Technology
Assessment
programme
interferon beta for multiple
sclerosis [Preview]
57 1998 HTA Canadian
Coordinating
Office for Health
Technology
Assessment
(CCOHTA)
Comparison of drug treatments
for multiple sclerosis - systematic
review [Preview]
58 1998 HTA NIHR Health
Technology
Assessment
programme
Cost-effectiveness of interferon
beta for multiple sclerosis: the
implications of new information
on clinical effectiveness [Preview]
59 1997 HTA Wessex Institute
for Health
Research and
Development
(WIHRD)
Interferon beta-1a in relapsing-
remitting multiple sclerosis [Preview]
60 1996 HTA Canadian
Coordinating
Office for
Health
Technology
Assessment
(CCOHTA)
A therapeutic and economic
assessment of Betaseron in
multiple sclerosis - systematic
review [Preview]
1996
61
HTA Wessex Institute for
Health
Research and
Development
(WIHRD)
Copolymer 1 in relapsing-
remitting multiple sclerosis [Preview]
62
1996 HTA Canadian Coordinating Office for Health Technology
Assessment (CCOHTA)
Interferon beta
1-b and multiple
sclerosis -
summary [Preview]
63 1996 HTA Health Council of the
Netherlands/Gezondheidsraad
(GR)
Interferon-beta-
1b in patients
with multiple
sclerosis [Preview]
23
64 HTA NIHR Health Technology
Assessment programme Cannabinoids
(cannabis
derivatives) for
treatment of the
symptoms of
multiple
sclerosis [Preview]
65 HTA Catalan Agency for Health
Information, Assessment and
Quality (CAHIAQ -formerly
CAHTA)
Clinical practice
guideline on
multiple
sclerosis [Preview]
66 HTA NIHR Health Technology
Assessment programme Fingolimod for
relapsing or
remitting
multiple
sclerosis [Preview]
67 HTA NIHR Health Technology
Assessment programme Natalizumab for
multiple
sclerosis [Preview]
Cochrane Database
Søgt på: ”multiple sclerosis”[MESH] and (rehabilitation or "daily living" or physiotherapy or "physical therapy" or "occupational therapy" or functioning):ti,ab,kw 16 fund
option1
24
Occupational therapy for multiple sclerosis
Esther EMJ Steultjens , Joost J Dekker , Lex M Bouter , Mieke M Cardol , Els
CHM Van den Ende and Jos van de Nes
January 2009
1. Review
option2
Whole‐ body vibration training for patients with neurodegenerative disease
Mercè Sitjà Rabert , David Rigau Comas , Azahara Fort Vanmeerhaeghe ,
Carme Santoyo Medina , Marta Roqué i Figuls , Daniel Romero‐Rodríguez and
Xavier Bonfill Cosp
February 2012
1. Review
option3
Memory Rehabilitation for people with multiple sclerosis
Roshan das Nair , Heather Ferguson , Daniel L Stark and Nadina B Lincoln
March 2012
1. Review
option4
Neuropsychological rehabilitation for multiple sclerosis
Eija M Rosti‐Otajärvi and Päivi I Hämäläinen
November 2011
1. Review
option5
Psychological interventions for multiple sclerosis
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003608/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009097.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008754.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009131.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004431.pub2/abstract
25
Peter W Thomas , Sarah Thomas , Charles Hillier , Kate Galvin and Roger Baker
January 2009
1. Review
option6
Multidisciplinary rehabilitation for adults with multiple sclerosis
Fary Khan , Lynne Turner‐Stokes , Louisa Ng , Trevor Kilpatrick and Bhasker
Amatya
December 2011
1. Ns 2. Review
option7
Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis
Fary Khan , Louisa Ng and Lynne Turner‐Stokes
December 2011
1. Ns 2. Review
option8
Exercise therapy for multiple sclerosis
Marc B Rietberg , Dina Brooks , Bernard MJ Uitdehaag and Gert Kwakkel
January 2011
1. Review
option9
Interventions for fatigue and weight loss in adults with advanced progressive illness
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006036.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007256.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007256.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003980.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008427.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008427.pub2/abstract
26
Cathy Payne , Philip J Wiffen and Suzanne Martin
August 2012
1. Review
option10
Treatment for ataxia in multiple sclerosis
Roger J Mills , Leesien Yap and Carolyn A Young
January 2009
1. Review
option11
Amantadine for fatigue in multiple sclerosis
Eugenio Pucci , Pedro Brañas Tato , Roberto D'Amico , Giorgio Giuliani ,
Alessandra Solari and Cristiana Taus
January 2009
1. Review
option12
Non pharmacological interventions for spasticity in multiple sclerosis
Bhasker Amatya , Fary Khan , Loredana La Mantia , Marina Demetrios and
Derick T Wade
February 2013
1. Review
option13
Aminopyridines for symptomatic treatment in multiple sclerosis
Alessandra Solari , Bernard MJ Uitdehaag , Giorgio Giuliani , Eugenio Pucci and
Cristiana Taus
January 2009
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005029.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002818.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009974.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001330/abstract
27
1. Review
option14
Anti‐ spasticity agents for multiple sclerosis
David Shakespeare , Mike Boggild and Carolyn A Young
January 2009
1. Review
option15
Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis
Yousheng Xiao , Jin Wang and Hongye Luo
April 2012
1. Review
option16
Interferon beta for secondary progressive multiple sclerosis
Loredana La Mantia , Laura Vacchi , Carlo Di Pietrantonj , George Ebers , Marco
Rovaris , Sten Fredrikson and Graziella Filippini
January 2012
1. Review
SBU (Sverige)
Søgt på: multiple sclerosis / Multipel skleros
0 fund
Socialstyrelsen (Sverige)
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001332/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009427.pub2/abstracthttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005181.pub3/abstract
28
Søgt på: multiple sclerosis / Multipel skleros
3 fund
1. Rehabilitering vid kroniska neurologiska sjukdomar Datum: 2012-12-03 Visa med sökorden markerade Titel: - Rehabilitering vid kroniska neurologiska sjukdomar - Startdatum: - 2013-09-09 ...
vid kroniska neurologiska sjukdomar: Multipel skleros, Parkinsons sjukdom, postpolio,
neuromuskulära ... neurologiska sjukdomar. - Dag 1, em: Multipel skleros - Dag 2, fm:
Parkinsons sjukdom ...
Sökväg:
Start / SK-kurser / Rehabilitering vid kroniska ne...
2. Centrala rekommendationer i
demensriktlinjerna
Share on facebookShare on twitterShare on emailShare on print
Skriv ut
Här hittar du centrala rekommendationer som kan komma att påverka praxis och påverka
resursfördelningen inom vård och omsorg vid demenssjukdom.
Syftet med rekommendationerna är ge vägledning för beslut om resursfördelning på
gruppnivå.
Välj det område du vill läsa mer om
Att förebygga demenssjukdom
Utredning o Utredning och diagnostik
o Tidig social utredning och regelbunden strukturerad uppföljning
Organisation o Multiprofessionellt teambaserat arbete
o Utbildning av personal
Aktiviteter, fysisk träning och hjälpmedel Dagverksamhet Flytt och särskilt boende Stöd till anhöriga
Omvårdnad o Personcentrerad omvårdnad
http://www.socialstyrelsen.se/sk-kurser/rehabiliteringvidkroniskaneurohttp://www.socialstyrelsen.se/_layouts/Precio/SiteSeeker/ShowCache.aspx?resid=82423444&q=Multipel+skleros&il=sv&hitnr=2&url=http%3a%2f%2fwww.socialstyrelsen.se%2fsk-kurser%2frehabiliteringvidkroniskaneuro&uaid=16ABBB754F9623A2C8E39577D96BC389%253http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/javascript:window.print();javascript:window.print();http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/forebyggahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/utredninghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/organisationhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/aktiviteterhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/dagverksamhethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/boendehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/anhorigahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/omvardnad
29
o Rekommendationer för professionen
o Pallitativ vård i livets slutskede
Läkemedelsbehandling Beteendemässiga- och psykiska symtom vid demenssjukdom och konfusion
3. Sök i demensriktlinjerna
Share on facebookShare on twitterShare on emailShare on print
Skriv ut
Här kan du söka i Nationella riktlinjer för vård och omsorg vid demenssjukdom. Sök i
fritextrutan, med hjälp av filtreringsalternativen till vänster eller sortera i listan nedan.
Nedan kan du också ladda ner samtliga rekommendationer i tillstånds- och åtgärdslistan
och det vetenskapliga underlaget.
Tillstånds- och åtgärdslista
Vetenskapligt underlag
Tillstånd Åtgärd Rekommendation
Anhöriga till personer med demenssjukdom
Psykosociala stödprogram 2
Anhöriga till personer med demenssjukdom
Kombinationsprogram 3
Anhöriga till personer med demenssjukdom
Avlösning 2
Anhöriga till personer med demenssjukdom
Psykosocialt stöd på distans 6
Anhöriga till yngre personer med demenssjukdom
Specifikt anpassat stöd 3
Anhöriga till yngre personer med demenssjukdom
Individuellt anpassad avlösning 3
Beteendemässiga och psykiska symtom vid Alzheimers sjukdom
Behandling med antiepileptika
(karbamazepin, valproat, topiramat) Icke-göra
Friska personer Mentalt och socialt stimulerande aktiviteter på fritiden för att
förebygga demenssjukdom
3
Friska personer Fysisk aktivitet för att förebygga demenssjukdom
3
http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/lakemedelhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/centralarekommendationer/bpsdhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/javascript:window.print();javascript:window.print();http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-tillstandsochatgardslista.xlshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-tillstandsochatgardslista.xlshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-vetenskapligtunderlag.pdfhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/Documents/nr-demens-vetenskapligtunderlag.pdfjavascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemensshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemensshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillpersonermeddemenss3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermeddehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermeddehttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermedde1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/anhorigatillyngrepersonermedde1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/beteendemassiga-ochpsykiskasymhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/beteendemassiga-ochpsykiskasymhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersonerhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersoner1
30
Tillstånd Åtgärd Rekommendation
Friska personer Testning av riskgenen ApoE4 Icke-göra
Friska personer i medelåldern Behandling av högt blodtryck för att förebygga demenssjukdom
3
Kvinnor med måttlig till svår demensjukdom och urininkontinens
Bäckenbottenträning Icke-göra
Närstående till personer med demenssjukdom
Utbildningsprogram 2
Personer med agitation, aggressivitet eller vanföreställningar (hallucinationer) vid måttlig till...
Behandling med antipsykosmedel
(haloperidol) 8
Personer med agitation, aggressivitet eller vanföreställningar (hallucinationer) vid måttlig till...
Behandling med antipsykosmedel
(risperidon) 7
Personer med agitation, aggressivitet eller vanföreställningar (hallucinationer) vid måttlig till...
Behandling med antipsykosmedel
(olanzapin) 9
Personer med Alzheimers sjukdom Regelbunden, minst årlig, bedömning av behandlingslängd och
utsättningsförsök vid behandling
med...
1
Personer med Alzheimers sjukdom i särskilt boende
Kombinerad träning -
individanpassad, funktionell träning
med medelhög intensitet
5
Personer med Alzheimers sjukdom i särskilt boende
Individanpassade
träningspromenader 7
Personer med Alzheimers sjukdom och Downs syndrom
Behandling med
kolinesterashämmare 2
Personer med beteendemässiga och psykiska symtom vid Alzheimers sjukdom
Behandling med
kolinesterashämmare (donepezil,
galantamin, rivastagmin)
10
Personer med beteendemässiga och psykiska symtom vid Alzheimers sjukdom
Behandling med memantin 6
Personer med beteendemässiga och psykiska symtom vid demenssjukdom
Utredning och behandling av
bakomliggande orsaker 1
Personer med beteendemässiga och psykiska symtom vid demenssjukdom
Behandling till natten med
klometiazol 8
Personer med beteendemässiga Behandling med antipsykosmedel Icke-göra
javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersoner2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/friskapersonerimedelaldernhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/kvinnormedmattligtillsvardemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/kvinnormedmattligtillsvardemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/narstaendetillpersonermeddemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/narstaendetillpersonermeddemenhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivihttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedagitaion-aggressivi2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomishttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomishttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomis1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomis1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomochttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedalzheimerssjukdomochttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-ochhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbeteendemassiga-och3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svar
31
Tillstånd Åtgärd Rekommendation
och psykiska symtom vid måttlig till svår demenssjukdom
(quetiapin)
Personer med demenssjukdom Tidig social utredning 1
Personer med demenssjukdom Årlig medicinsk och social uppföljning
1
Personer med demenssjukdom Personcentrerad omvårdnad 1
Personer med demenssjukdom Utbildning av personal för att förebygga och upptäcka vanvård
1
Personer med demenssjukdom Reminiscence 8
Personer med demenssjukdom Validation 8
Personer med demenssjukdom Multiprofessionellt teambaserat arbete inom vård och omsorg
2
Personer med demenssjukdom Utbildning av personal i vård, omvårdnad och omsorg
6
Personer med demenssjukdom Långsiktig personalutbildning som är kombinerad med praktisk träning,
handledning och feedback
1
Personer med demenssjukdom Handledning i kombination med utbildning till personal
3
Personer med demenssjukdom Behandling med omega-3-fettsyror FoU
Personer med demenssjukdom Behandling med vitamin E eller vitamin C
FoU
Personer med demenssjukdom i livets slutskede
Palliativ vård 1
Personer med demenssjukdom i särskilt boende
Multifaktoriell intervention (flera
samtidiga åtgärder) för att förebygga
fall
1
Personer med demenssjukdom i särskilt boende
Kombinerad träning -
individanpassad, funktionell träning
med medelhög till hög intensitet
5
Personer med demenssjukdom i särskilt boende och på sjukhus
Översyn av läkemedel för att
förebygga fall 1
Personer med demenssjukdom inom särskilt boende
Personligt utformade, berikade och
hemlika fysiska boendemiljöer 1
Personer med demenssjukdom och aggressivitet
Beteendetekniker 10
Personer med demenssjukdom och aggressivitet
Validation 10
Personer med demenssjukdom och aggressivitet
Fysisk aktivitet 5
Personer med demenssjukdom och Personal som kommunicerar på 2
javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svarhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermedbpsdvidmattlig-svarhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom4http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom5http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom6http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom7http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom8http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom9http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom10http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdom11http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomilivethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomilivethttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarskhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarskhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomisarsk1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdominomsahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdominomsahttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagghttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochagg2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochann
32
Tillstånd Åtgärd Rekommendation
annan etnisk bakgrund samma modersmål med kulturkompetens
Personer med demenssjukdom och fysiska begränsningsåtgärder
Kontinuerliga observationer och
utvärderingar 1
Personer med demenssjukdom och fysiska begränsningsåtgärder
Utbildning och handledning av
personal för att minska användandet
av fysiska begränsningsåtgärder
1
Personer med demenssjukdom och förstoppning
Magmassage 8
Personer med demenssjukdom och förstoppning eller risk för förstoppning
Behandling med paraffinolja Icke-göra
Personer med demenssjukdom och förstoppning eller risk för förstoppning
Biofeedback (träning av
muskelkoordination) Icke-göra
Personer med demenssjukdom och förstoppning eller risk för förstoppning
Regelbundna toalettvanor 1
Personer med demenssjukdom och konfusion
Läkemedelsbehandling med
antipsykosmedel (haloperidol,
risperidon)
8
Personer med demenssjukdom och konfusion
Läkemedelsbehandling med
olanzapin Icke-göra
Personer med demenssjukdom och konfusion
Aktivering dagtid med tillägg av
klometiazol nattetid 8
Personer med demenssjukdom och misstänkt konfusion
Utredning och behandling av
bakomliggande orsaker 1
Personer med demenssjukdom och risk för förstoppning
Fiberrik kost och ett adekvat
vätskeintag genom tillförsel av
vätska
1
Personer med demenssjukdom och risk för förstoppning
Fysisk aktivitet 1
Personer med demenssjukdom och risk för nedsatt munhälsa
Strukturerad bedömning av
munhälsa 1
Personer med demenssjukdom och skrikbeteende
Beteendetekniker 10
Personer med demenssjukdom och undernäring
Nutritionsintervention -
energiberikning av mat och dryck,
extra mellanmål,
konsistensanpassning
1
Personer med demenssjukdom och undernäring
Nutritionsintervention i form av
tillägg av näringsdrycker 5
javascript:knowledgeDatabaseSearch('tillstand',%20'sort|UP')javascript:knowledgeDatabaseSearch('atgard',%20'sort|UP')javascript:knowledgeDatabaseSearch('rekommendation',%20'sort|UP')http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochannhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfyshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfyshttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfys1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfys1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochforhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochfor3http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkonhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkonhttp://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon1http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personermeddemenssjukdomochkon2http://www.socialstyrelsen.se/nationellariktlinjerforvardochomsorgviddemenssjukdom/sokiriktlinjerna/personerme